Jun Kawashima

Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial

Claire Harrison, Alessandro M. Vannucchi, Uwe Platzbecker et al. · The Lancet Haematology · 2017 · 301 citations

Hematological Malignancy, Momelotinib Versus, Simplify 2 +5

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Srđan Verstovšek, Aaron T. Gerds, Alessandro M. Vannucchi et al. · The Lancet · 2023 · 164 citations

Hematological Malignancy, Bone Marrow Failure, Momelotinib Versus Danazol +6

ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial

Stephen T. Oh, Moshe Talpaz, Aaron T. Gerds et al. · Blood Advances · 2020 · 119 citations · Full text

A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis

Vikas Gupta, Ruben A. Mesa, Michael W. Deininger et al. · Haematologica · 2016 · 94 citations · Full text

Update On The Long-Term Efficacy and Safety Of Momelotinib, a JAK1 and JAK2 Inhibitor, For The Treatment Of Myelofibrosis

Animesh Pardanani, Jason Gotlib, Vikas Gupta et al. · Blood · 2013 · 44 citations